Drug Interactions between Carafate and infliximab
This report displays the potential drug interactions for the following 2 drugs:
- Carafate (sucralfate)
- infliximab
Interactions between your drugs
No interactions were found between Carafate and infliximab. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Carafate
A total of 159 drugs are known to interact with Carafate.
- Carafate is in the drug class miscellaneous GI agents.
- Carafate is used to treat the following conditions:
infliximab
A total of 568 drugs are known to interact with infliximab.
- Infliximab is in the following drug classes: antirheumatics, TNF alfa inhibitors.
-
Infliximab is used to treat the following conditions:
- Ankylosing Spondylitis
- Behcet's Disease (off-label)
- Bullous Pemphigoid (off-label)
- Celiac Disease (off-label)
- Cogan's Syndrome (off-label)
- Crohn's Disease
- Crohn's Disease, Active
- Crohn's Disease, Maintenance
- Giant Cell Arteritis (off-label)
- Inflammatory Bowel Disease
- Kawasaki Disease (off-label)
- Neurosarcoidosis (off-label)
- Pemphigoid (off-label)
- Pemphigus (off-label)
- Plaque Psoriasis
- Polychondritis (off-label)
- Psoriasis
- Psoriatic Arthritis
- Pulmonary Fibrosis (off-label)
- Pyoderma Gangrenosum (off-label)
- Rheumatoid Arthritis
- SAPHO Syndrome (off-label)
- Sarcoidosis (off-label)
- Sjogren's Syndrome (off-label)
- Spondyloarthritis (off-label)
- Subcorneal Pustular Dermatosis (off-label)
- Toxic Epidermal Necrolysis (off-label)
- Ulcerative Colitis
- Ulcerative Colitis, Maintenance
- Uveitis (off-label)
Drug and food interactions
sucralfate food
Applies to: Carafate (sucralfate)
ADJUST DOSING INTERVAL: The administration of sucralfate with enteral nutrition may result in precipitation and the formation of bezoars that may obstruct feeding tubes. The proposed mechanism is the formation of an insoluble aluminum-protein complex between the aluminum in the sucralfate and the protein in the enteral feeding. In addition, sucralfate may not become activated due to the alkaline pH of enteral nutrition products.
MANAGEMENT: Some experts recommend separating the sucralfate doses from enteral feedings by at least 1 hour. Alternatively, consideration may be given to proton pump inhibitors or H2 antagonists.
References (1)
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.